Cited 69 times in
Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 서진석 | - |
dc.contributor.author | 손혜영 | - |
dc.contributor.author | 허용민 | - |
dc.date.accessioned | 2017-10-26T07:21:26Z | - |
dc.date.available | 2017-10-26T07:21:26Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/151922 | - |
dc.description.abstract | The cancer stem cell (CSC) hypothesis postulates that cancer cells overexpressing CD44 are marked as CSCs that cause tumorigenesis and recurrence. This hypothesis suggests that CD44 is a potential therapeutic target that can interfere with CSCs qualities. MicroRNA-34a (miR-34a) is a promising candidate for CD44 repression-based cancer therapy as it has been reported to inhibit proliferation, metastasis, and survival of CD44-positive CSCs. Here, we used nanovesicles containing PLI/miR complexes (NVs/miR) to systemically deliver miR-34a and induce miR-34a-triggered CD44 suppression in orthotopically and subcutaneously implanted tumors in nude mice. Poly(l-lysine-graft-imidazole) (PLI) condenses miRs and is functionally modified to deliver miRs to the site of action by buffering effect of imidazole residues under endosomal pH. Indeed, NVs/miR consisting of PEGylated lipids enveloping PLI/miR complexes greatly reduced inevitable toxicity of polycations by compensating their surface charge and markedly improved their in vivo stability and accumulation to tumor tissue compared to PLI/miR polyplexes. Our NVs-mediated miR-34a delivery system specifically increased endogenous target miR levels, thereby attenuating proliferation and migration of gastric cancer cells by repressing the expression of CD44 with decreased levels of Bcl-2, Oct 3/4 and Nanog genes. Our strategy led to a greater therapeutic outcome than PLI-based delivery with highly selective tumor cell death and significantly delayed tumor growth in CD44-positive tumor-bearing mouse models, thus providing a fundamental therapeutic window for CSCs. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.publisher | Elsevier Science | - |
dc.relation.isPartOf | BIOMATERIALS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hyaluronan Receptors/metabolism* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred BALB C | - |
dc.subject.MESH | MicroRNAs/administration & dosage* | - |
dc.subject.MESH | Molecular Targeted Therapy/methods | - |
dc.subject.MESH | Nanocapsules/administration & dosage* | - |
dc.subject.MESH | Nanocapsules/chemistry | - |
dc.subject.MESH | Nanoconjugates/administration & dosage | - |
dc.subject.MESH | Nanoconjugates/chemistry | - |
dc.subject.MESH | Neoplastic Stem Cells/drug effects* | - |
dc.subject.MESH | Neoplastic Stem Cells/metabolism* | - |
dc.subject.MESH | Neoplastic Stem Cells/pathology | - |
dc.subject.MESH | Stomach Neoplasms/metabolism* | - |
dc.subject.MESH | Stomach Neoplasms/therapy* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy | - |
dc.type | Article | - |
dc.publisher.location | Netherlands | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Radiology | - |
dc.contributor.googleauthor | Eunji Jang | - |
dc.contributor.googleauthor | Eunjung Kim | - |
dc.contributor.googleauthor | Hye-Young Son | - |
dc.contributor.googleauthor | Eun-Kyung Lim | - |
dc.contributor.googleauthor | Hwunjae Lee | - |
dc.contributor.googleauthor | Yuna Choi | - |
dc.contributor.googleauthor | Kwangyeol Park | - |
dc.contributor.googleauthor | Seungmin Han | - |
dc.contributor.googleauthor | Jin-Suck Suh | - |
dc.contributor.googleauthor | , Yong-Min Huh | - |
dc.contributor.googleauthor | Seungjoo Haam | - |
dc.identifier.doi | 10.1016/j.biomaterials.2016.07.036 | - |
dc.contributor.localId | A04589 | - |
dc.contributor.localId | A04359 | - |
dc.contributor.localId | A01916 | - |
dc.relation.journalcode | J00312 | - |
dc.identifier.eissn | 1878-5905 | - |
dc.identifier.pmid | 27497057 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0142961216303738?via%3Dihub | - |
dc.subject.keyword | CD44 suppression | - |
dc.subject.keyword | Cancer stem cells | - |
dc.subject.keyword | Nanovesicles | - |
dc.subject.keyword | miR-34a delivery | - |
dc.subject.keyword | pH-responsive | - |
dc.contributor.alternativeName | Suh, Jin Suck | - |
dc.contributor.alternativeName | Son, Hye Yeong | - |
dc.contributor.alternativeName | Huh, Yong Min | - |
dc.contributor.affiliatedAuthor | Son, Hye Yeong | - |
dc.contributor.affiliatedAuthor | Huh, Yong Min | - |
dc.contributor.affiliatedAuthor | Suh, Jin Suck | - |
dc.citation.volume | 105 | - |
dc.citation.startPage | 12 | - |
dc.citation.endPage | 24 | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, Vol.105 : 12-24, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 46247 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.